Medherant is developing a new ibuprofen transdermal patch to fill a conspicuous gap in the ibuprofen market, currently worth over *$4bn.
TEPI Patch Ibuprofen

Using our TEPI Patch technology, the patch will offer high drug loading with a tailored delivery profile without a loss of adhesion strength. TEPI Patch has a consumer friendly design that is easy to apply and easy to remove, yet still highly adhesive.

Medherant is developing an Ibuprofen transdermal patch with a tailored delivery profile, efficient adherence and a consumer friendly design.

Medherant is developing an Ibuprofen transdermal patch with a tailored delivery profile, efficient adherence and a consumer friendly design.

The transparent adhesive patch can deliver a prolonged high dose of ibuprofen at a consistent dose rate for up to 24 hours. Significant amounts of the drug (up to 30% weight) are incorporated into the polymer matrix that sticks the patch to the patient’s skin with the drug then being delivered at a steady rate over at least 12 hours.

This opens the way for the development of a range of novel long-acting over-the-counter pain relief products, which can be used to treat common painful conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.

* Euromonitor and EvaluatePharma